Artificial intelligence (AI) studies show promise in enhancing accuracy and efficiency in mammographic screening programs worldwide. However, its integration into clinical workflows faces several challenges, including unintended errors, the need for professional training, and ethical concerns. Notably, specific frameworks for AI imaging in breast cancer screening are still lacking. This study aims to identify the challenges associated with implementing AI in breast screening programs and to apply the Consolidated Framework for Implementation Research (CFIR) to discuss a practical governance framework for AI in this context. Three electronic databases (PubMed, Embase, and MEDLINE) were searched using combinations of the keywords "artificial intelligence," "regulation," "governance," "breast cancer," and "screening." Original studies evaluating AI in breast cancer detection or discussing challenges related to AI implementation in this setting were eligible for review. Findings were narratively synthesized and subsequently mapped directly onto the constructs within the CFIR. A total of 1240 results were retrieved, with 20 original studies ultimately included in this systematic review. The majority (n=19) focused on AI-enhanced mammography, while 1 addressed AI-enhanced ultrasound for women with dense breasts. Most studies originated from the United States (n=5) and the United Kingdom (n=4), with publication years ranging from 2019 to 2023. The quality of papers was rated as moderate to high. The key challenges identified were reproducibility, evidentiary standards, technological concerns, trust issues, as well as ethical, legal, societal concerns, and postadoption uncertainty. By aligning these findings with the CFIR constructs, action plans targeting the main challenges were incorporated into the framework, facilitating a structured approach to addressing these issues. This systematic review identifies key challenges in implementing AI in breast cancer screening, emphasizing the need for consistency, robust evidentiary standards, technological advancements, user trust, ethical frameworks, legal safeguards, and societal benefits. These findings can serve as a blueprint for policy makers, clinicians, and AI developers to collaboratively advance AI adoption in breast cancer screening. PROSPERO CRD42024553889; https://tinyurl.com/mu4nwcxt.

Chronic obstructive pulmonary disease (COPD) is a common and progressive respiratory condition characterized by persistent airflow limitation and symptoms such as dyspnea, cough, and sputum production. Acute exacerbations (AE) of COPD (AE-COPD) are key determinants of disease progression; yet, existing predictive models relying mainly on spirometric measurements, such as forced expiratory volume in 1 second, reflect only a fraction of the physiological information embedded in respiratory function tests. Recent advances in artificial intelligence (AI) have enabled more sophisticated analyses of full spirometric curves, including flow-volume loops and volume-time curves, facilitating the identification of complex patterns associated with increased exacerbation risk. This study aimed to determine whether a predictive model that integrates clinical data and spirometry images with the use of AI improves accuracy in predicting moderate-to-severe and severe AE-COPD events compared to a clinical-only model. A retrospective cohort study was conducted using COPD registry data from 2 teaching hospitals from January 2004 to December 2020. The study included a total of 10,492 COPD cases, divided into a development cohort (6870 cases) and an external validation cohort (3622 cases). The AI-enhanced model (AI-PFT-Clin) used a combination of clinical variables (eg, history of AE-COPD, dyspnea, and inhaled treatments) and spirometry image data (flow-volume loop and volume-time curves). In contrast, the Clin model used only clinical variables. The primary outcomes were moderate-to-severe and severe AE-COPD events within a year of spirometry. In the external validation cohort, the AI-PFT-Clin model outperformed the Clin model, showing an area under the receiver operating characteristic curve of 0.755 versus 0.730 (P<.05) for moderate-to-severe AE-COPD and 0.713 versus 0.675 (P<.05) for severe AE-COPD. The AI-PFT-Clin model demonstrated reliable predictive capability across subgroups, including younger patients and those without previous exacerbations. Higher AI-PFT-Clin scores correlated with elevated AE-COPD risk (adjusted hazard ratio for Q4 vs Q1: 4.21, P<.001), with sustained predictive stability over a 10-year follow-up period. The AI-PFT-Clin model, by integrating clinical data with spirometry images, offers enhanced predictive accuracy for AE-COPD events compared to a clinical-only approach. This AI-based framework facilitates the early identification of high-risk individuals through the detection of physiological abnormalities not captured by conventional metrics. The model's robust performance and long-term predictive stability suggest its potential utility in proactive COPD management and personalized intervention planning. These findings highlight the promise of incorporating advanced AI techniques into routine COPD management, particularly in populations traditionally seen as lower risk, supporting improved management of COPD through tailored patient care.

Ultrasound localization microscopy (ULM) has revolutionized microvascular imaging by breaking the acoustic diffraction limit. However, different ULM workflows depend heavily on distinct prior knowledge, such as the impulse response and empirical selection of parameters (e.g., the number of microbubbles (MBs) per frame M), or the consistency of training-test dataset in deep learning (DL)-based studies. We hereby propose a general ULM pipeline that reduces priors. Our approach leverages a DL model that simultaneously distills microbubble signals and reduces speckle from every frame without estimating the impulse response and M. Our method features an efficient channel attention vision transformer (ViT) and a progressive learning strategy, enabling it to learn global information through training on progressively increasing patch sizes. Ample synthetic data were generated using the k-Wave toolbox to simulate various MB patterns, thus overcoming the deficiency of labeled data. The ViT output was further processed by a standard radial symmetry method for sub-pixel localization. Our method performed well on model-unseen public datasets: one in silico dataset with ground truth and four in vivo datasets of mouse tumor, rat brain, rat brain bolus, and rat kidney. Our pipeline outperformed conventional ULM, achieving higher positive predictive values (precision in DL, 0.88-0.41 vs. 0.83-0.16) and improved accuracy (root-mean-square errors: 0.25-0.14 λ vs. 0.31-0.13 λ) across a range of signal-to-noise ratios from 60 dB to 10 dB. Our model could detect more vessels in diverse in vivo datasets while achieving comparable resolutions to the standard method. The proposed ViT-based model, seamlessly integrated with state-of-the-art downstream ULM steps, improved the overall ULM performance with no priors.

Positron Emission Tomography (PET) is an important clinical imaging tool but inevitably introduces radiation exposure to patients and healthcare providers. Reducing the tracer injection dose and eliminating the CT acquisition for attenuation correction can reduce the overall radiation dose, but often results in PET with high noise and bias. Thus, it is desirable to develop 3D methods to translate the non-attenuation-corrected low-dose PET (NAC-LDPET) into attenuation-corrected standard-dose PET (AC-SDPET). Recently, diffusion models have emerged as a new state-of-the-art deep learning method for image-to-image translation, better than traditional CNN-based methods. However, due to the high computation cost and memory burden, it is largely limited to 2D applications. To address these challenges, we developed a novel 2.5D Multi-view Averaging Diffusion Model (MADM) for 3D image-to-image translation with application on NAC-LDPET to AC-SDPET translation. Specifically, MADM employs separate diffusion models for axial, coronal, and sagittal views, whose outputs are averaged in each sampling step to ensure the 3D generation quality from multiple views. To accelerate the 3D sampling process, we also proposed a strategy to use the CNN-based 3D generation as a prior for the diffusion model. Our experimental results on human patient studies suggested that MADM can generate high-quality 3D translation images, outperforming previous CNN-based and Diffusion-based baseline methods. The code is available at https://github.com/tianqic/MADM.

As ultrasound (US) is the most accurate tool for assessing the thyroid nodule (TN) risk of malignancy (RoM), international societies have published various Thyroid Imaging and Reporting Data Systems (TIRADSs). With the recent advent of artificial intelligence (AI), clinicians and researchers should ask themselves how AI could interpret the terminology of the TIRADSs and whether or not AIs agree in the risk assessment of TNs. The study aim was to analyze the interobserver agreement (IOA) between AIs in assessing the RoM of TNs across various TIRADSs categories using a cases series created combining TIRADSs descriptors. ChatGPT, Google Gemini, and Claude were compared. ACR-TIRADS, EU-TIRADS, and K-TIRADS, were employed to evaluate the AI assessment. Multiple written scenarios for the three TIRADS were created, the cases were evaluated by the three AIs, and their assessments were analyzed and compared. The IOA was estimated by comparing the kappa (κ) values. Ninety scenarios were created. With ACR-TIRADS the IOA analysis gave κ = 0.58 between ChatGPT and Gemini, 0.53 between ChatGPT and Claude, and 0.90 between Gemini and Claude. With EU-TIRADS it was observed κ value = 0.73 between ChatGPT and Gemini, 0.62 between ChatGPT and Claude, and 0.72 between Gemini and Claude. With K-TIRADS it was found κ = 0.88 between ChatGPT and Gemini, 0.70 between ChatGPT and Claude, and 0.61 between Gemini and Claude. This study found that there were non-negligible variability between the three AIs. Clinicians and patients should be aware of these new findings.

Hepatocellular carcinoma (HCC) is an aggressive cancer with limited biomarkers for predicting immunotherapy response. Recent advancements in large language models (LLMs) like GPT-4, GPT-4o, and Gemini offer the potential for enhancing clinical decision-making through multimodal data analysis. However, their effectiveness in predicting immunotherapy response, especially compared to human experts, remains unclear. This study assessed the performance of GPT-4, GPT-4o, and Gemini in predicting immunotherapy response in unresectable HCC, compared to radiologists and oncologists of varying expertise. A retrospective analysis of 186 patients with unresectable HCC utilized multimodal data (clinical and CT images). LLMs were evaluated with zero-shot prompting and two strategies: the 'voting method' and the 'OR rule method' for improved sensitivity. Performance metrics included accuracy, sensitivity, area under the curve (AUC), and agreement across LLMs and physicians.GPT-4o, using the 'OR rule method,' achieved 65% accuracy and 47% sensitivity, comparable to intermediate physicians but lower than senior physicians (accuracy: 72%, p = 0.045; sensitivity: 70%, p < 0.0001). Gemini-GPT, combining GPT-4, GPT-4o, and Gemini, achieved an AUC of 0.69, similar to senior physicians (AUC: 0.72, p = 0.35), with 68% accuracy, outperforming junior and intermediate physicians while remaining comparable to senior physicians (p = 0.78). However, its sensitivity (58%) was lower than senior physicians (p = 0.0097). LLMs demonstrated higher inter-model agreement (κ = 0.59-0.70) than inter-physician agreement, especially among junior physicians (κ = 0.15). This study highlights the potential of LLMs, particularly Gemini-GPT, as valuable tools in predicting immunotherapy response for HCC.

To assess the agreement between lumbar disc degeneration (DD) grading by the convolutional neural network model SpineNet and radiologist's visual grading. In a 14-year follow-up MRI study involving 19 male volunteers, lumbar DD was assessed by SpineNet and two radiologists using the Pfirrmann classification at baseline (age 37) and after 14 years (age 51). Pfirrmann summary scores (PSS) were calculated by summing individual disc grades. The agreement between the first radiologist and SpineNet was analyzed, with the second radiologist's grading used for inter-observer agreement. Significant differences were observed in the Pfirrmann grades and PSS assigned by the radiologist and SpineNet at both time points. SpineNet assigned Pfirrmann grade 1 to several discs and grade 5 to more discs compared to the radiologists. The concordance correlation coefficients (CCC) of PSS between the radiologist and SpineNet were 0.54 (95% CI: 0.28 to 0.79) at baseline and 0.54 (0.27 to 0.80) at follow-up. The average kappa (κ) values of 0.74 (0.68 to 0.81) at baseline and 0.68 (0.58 to 0.77) at follow-up. CCC of PSS between the radiologists was 0.83 (0.69 to 0.97) at baseline and 0.78 (0.61 to 0.95) at follow-up, with κ values ranging from 0.73 to 0.96. We found fair to substantial agreement in DD grading between SpineNet and the radiologist, albeit with notable discrepancies. These findings indicate that AI-based systems like SpineNet hold promise as complementary tools in radiological evaluation, including in longitudinal studies, but emphasize the need for ongoing refinement of AI algorithms.

CBCT has become an essential tool in orthodontics, although its use must remain judicious and evidence-based. This study provides an updated analysis of international recommendations concerning the use of CBCT in orthodontics, with a particular focus on clinical indications, radiation dose reduction, and recent technological advancements. A systematic review of guidelines published between 2015 and 2025 was conducted following the PRISMA methodology. Inclusion criteria comprised official directives from recognized scientific societies and clinical studies evaluating low dose protocols in orthodontics. The analysis of the 19 retained recommendations reveals a consensus regarding the primary indications for CBCT in orthodontics, particularly for impacted teeth, skeletal anomalies, periodontal and upper airways assessment. Dose optimization and the integration of artificial intelligence emerge as major advancements, enabling significant radiation reduction while preserving diagnostic accuracy. The development of low dose protocols and advanced reconstruction algorithms presents promising perspectives for safer and more efficient imaging, increasingly replacing conventional 2D radiographic techniques. However, an international harmonization of recommendations for these new imaging sequences is imperative to standardize clinical practices and enhance patient radioprotection.

Information overload in electronic health records requires effective solutions to alleviate clinicians' administrative tasks. Automatically summarizing clinical text has gained significant attention with the rise of large language models. While individual studies show optimism, a structured overview of the research landscape is lacking. This study aims to present the current state of the art on clinical text summarization using large language models, evaluate the level of evidence in existing research and assess the applicability of performance findings in clinical settings. This scoping review complied with the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. Literature published between January 1, 2019, and June 18, 2024, was identified from 5 databases: PubMed, Embase, Web of Science, IEEE Xplore, and ACM Digital Library. Studies were excluded if they did not describe transformer-based models, did not focus on clinical text summarization, did not engage with free-text data, were not original research, were nonretrievable, were not peer-reviewed, or were not in English, French, Spanish, or German. Data related to study context and characteristics, scope of research, and evaluation methodologies were systematically collected and analyzed by 3 authors independently. A total of 30 original studies were included in the analysis. All used observational retrospective designs, mainly using real patient data (n=28, 93%). The research landscape demonstrated a narrow research focus, often centered on summarizing radiology reports (n=17, 57%), primarily involving data from the intensive care unit (n=15, 50%) of US-based institutions (n=19, 73%), in English (n=26, 87%). This focus aligned with the frequent reliance on the open-source Medical Information Mart for Intensive Care dataset (n=15, 50%). Summarization methodologies predominantly involved abstractive approaches (n=17, 57%) on single-document inputs (n=4, 13%) with unstructured data (n=13, 43%), yet reporting on methodological details remained inconsistent across studies. Model selection involved both open-source models (n=26, 87%) and proprietary models (n=7, 23%). Evaluation frameworks were highly heterogeneous. All studies conducted internal validation, but external validation (n=2, 7%), failure analysis (n=6, 20%), and patient safety risks analysis (n=1, 3%) were infrequent, and none reported bias assessment. Most studies used both automated metrics and human evaluation (n=16, 53%), while 10 (33%) used only automated metrics, and 4 (13%) only human evaluation. Key barriers hinder the translation of current research into trustworthy, clinically valid applications. Current research remains exploratory and limited in scope, with many applications yet to be explored. Performance assessments often lack reliability, and clinical impact evaluations are insufficient raising concerns about model utility, safety, fairness, and data privacy. Advancing the field requires more robust evaluation frameworks, a broader research scope, and a stronger focus on real-world applicability.

Biochemical recurrence (BCR) after radical prostatectomy exhibits heterogeneous prognostic implications. Recent advancements in imaging and biomarkers have high potential for personalizing care. Prostate-specific membrane antigen imaging (PSMA)-PET/CT has revolutionized the BCR management in prostate cancer by detecting microscopic lesions earlier than conventional staging, leading to improved cancer control outcomes and changes in treatment plans in approximately two-thirds of cases. Salvage radiotherapy, often combined with androgen deprivation therapy, remains the standard treatment for high-risk BCR postprostatectomy, with PSMA-PET/CT guiding treatment adjustments, such as the radiation field, and improving progression-free survival. Advancements in biomarkers, genomic classifiers, and artificial intelligence-based models have enhanced risk stratification and personalized treatment planning, resulting in both treatment intensification and de-escalation. While conventional risk grouping relying on Gleason score and PSA level and kinetics remain the foundation for BCR management, PSMA-PET/CT, novel biomarkers, and artificial intelligence may enable more personalized treatment strategies.